FORA Capital LLC Makes New Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

FORA Capital LLC purchased a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,226 shares of the company’s stock, valued at approximately $399,000.

A number of other hedge funds also recently modified their holdings of the business. Quest Partners LLC increased its stake in Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after purchasing an additional 1,127 shares in the last quarter. Amalgamated Bank increased its position in shares of Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after acquiring an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $213,000. Finally, Creative Planning bought a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $249,000.

Insider Transactions at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00. Following the completion of the sale, the senior vice president now directly owns 2,426 shares of the company’s stock, valued at approximately $114,264.60. This trade represents a 50.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 22.87% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Stock Down 0.9 %

Mirum Pharmaceuticals stock opened at $46.22 on Friday. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $48.89. The firm has a market capitalization of $2.22 billion, a PE ratio of -22.88 and a beta of 1.16. The company’s 50-day moving average is $40.93 and its 200-day moving average is $37.31. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same period in the previous year, the firm earned ($0.57) EPS. The firm’s revenue was up 89.4% compared to the same quarter last year. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MIRM. Cantor Fitzgerald lifted their price target on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners boosted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Citigroup increased their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $57.73.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.